• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Director Kitayama Mitchell W was granted 6,449 shares, increasing direct ownership by 44% to 21,060 units (SEC Form 4)

    6/13/25 4:19:23 PM ET
    $ASTH
    Professional Services
    Consumer Discretionary
    Get the next $ASTH alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Kitayama Mitchell W

    (Last) (First) (Middle)
    C/O ASTRANA HEALTH, INC.
    1668 S. GARFIELD AVE, 2ND FLOOR

    (Street)
    ALHAMBRA CA 91801

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Astrana Health, Inc. [ ASTH ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/11/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/11/2025 A 6,449(1) A $0 21,060(2) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Restricted shares of the Issuer's common stock granted pursuant to the Issuer's 2024 Equity Incentive Plan, which will vest on the earlier of (i) June 11, 2026 or (ii) the date of the Issuer's 2026 annual meeting of stockholders.
    2. Includes 6,449 shares of restricted stock, which will vest on the earlier of June 11, 2026 or the date of the Issuer's 2026 annual meeting of stockholders.
    /s/ Kathy Diep, as Attorney-in-Fact 06/13/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ASTH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASTH

    DatePrice TargetRatingAnalyst
    12/12/2025$28.00Buy
    Needham
    4/1/2025$36.00Equal Weight
    Barclays
    10/14/2024$66.00Buy
    TD Cowen
    10/11/2024Sector Weight
    KeyBanc Capital Markets
    7/11/2024$44.00 → $50.00Hold → Buy
    Truist
    5/30/2024$54.00Outperform
    Robert W. Baird
    More analyst ratings

    $ASTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and President Sim Brandon exercised 21,334 shares at a strike of $23.24, increasing direct ownership by 2% to 1,045,329 units (SEC Form 4)

    4 - Astrana Health, Inc. (0001083446) (Issuer)

    2/3/26 9:37:01 PM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    Chief Medical Officer Kumar Dinesh M. covered exercise/tax liability with 10,759 shares, decreasing direct ownership by 5% to 202,032 units (SEC Form 4)

    4 - Astrana Health, Inc. (0001083446) (Issuer)

    1/27/26 5:01:15 PM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    Director Schmidt David exercised 20,000 shares at a strike of $5.79 and covered exercise/tax liability with 4,269 shares, increasing direct ownership by 100% to 31,494 units (SEC Form 4)

    4 - Astrana Health, Inc. (0001083446) (Issuer)

    1/15/26 4:15:11 PM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    $ASTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on Astrana Health with a new price target

    Needham initiated coverage of Astrana Health with a rating of Buy and set a new price target of $28.00

    12/12/25 8:48:58 AM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    Barclays initiated coverage on Astrana Health with a new price target

    Barclays initiated coverage of Astrana Health with a rating of Equal Weight and set a new price target of $36.00

    4/1/25 7:41:49 AM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    TD Cowen initiated coverage on Astrana Health with a new price target

    TD Cowen initiated coverage of Astrana Health with a rating of Buy and set a new price target of $66.00

    10/14/24 7:24:49 AM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    $ASTH
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Astrana Health Inc.

    SCHEDULE 13G/A - Astrana Health, Inc. (0001083446) (Subject)

    1/30/26 1:26:26 PM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    Astrana Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Astrana Health, Inc. (0001083446) (Filer)

    1/12/26 4:06:05 PM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    SEC Form D filed by Astrana Health Inc.

    D - Astrana Health, Inc. (0001083446) (Filer)

    11/21/25 4:15:27 PM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    $ASTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Astrana Health, Inc. Schedules 2025 Fourth Quarter and Year-End Financial Results Release and Conference Call

    ALHAMBRA, Calif., Jan. 26, 2026 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced that it will release financial results for the fourth quarter and year ended December 31, 2025, before the open of the stock market on Monday, March 2, 2026. The Company will discuss those results on a conference call at 5:30 a.m. PT/8:30 a.m. ET that same day.

    1/26/26 8:00:00 AM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    Astrana Health, Inc. to Participate in Upcoming Investor Conference

    ALHAMBRA, Calif., Jan. 6, 2026 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:ASTH), a physician-centric, technology-enabled healthcare company empowering providers to deliver accessible, high-quality, and high-value care to all, today announced that leadership is participating in the J.P. Morgan 2026 Healthcare Conference, being held in San Francisco, on Monday, January 12, 2026, including a presentation at 5:15pm PT. The webcast link and related presentation materials will be available in the "IR Calendar" section of the Company's website: https://ir.astranahealth.com/news-events/ir-calendar.

    1/6/26 8:07:00 AM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    Astrana Health, Inc. Reports Third Quarter 2025 Results

    Company to Host Conference Call on Thursday, November 6, 2025, at 2:30 p.m. PT/5:30 p.m. ET Reports total revenue of $956.0 million, up 100% year-over-year, and at the higher end of guidanceReports adjusted EBITDA of $68.5 million, at the higher end of guidanceCloses Prospect Health acquisition where standalone third quarter performance exceeded expectationsContinuing to control medical costs well; reiterating full-year trend expectationsUpdates full-year 2025 guidance to account for full-risk contract delays unrelated to core performanceALHAMBRA, Calif., Nov. 6, 2025 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (

    11/6/25 4:05:00 PM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    $ASTH
    Financials

    Live finance-specific insights

    View All

    Astrana Health, Inc. Schedules 2025 Fourth Quarter and Year-End Financial Results Release and Conference Call

    ALHAMBRA, Calif., Jan. 26, 2026 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced that it will release financial results for the fourth quarter and year ended December 31, 2025, before the open of the stock market on Monday, March 2, 2026. The Company will discuss those results on a conference call at 5:30 a.m. PT/8:30 a.m. ET that same day.

    1/26/26 8:00:00 AM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    Astrana Health, Inc. Reports Third Quarter 2025 Results

    Company to Host Conference Call on Thursday, November 6, 2025, at 2:30 p.m. PT/5:30 p.m. ET Reports total revenue of $956.0 million, up 100% year-over-year, and at the higher end of guidanceReports adjusted EBITDA of $68.5 million, at the higher end of guidanceCloses Prospect Health acquisition where standalone third quarter performance exceeded expectationsContinuing to control medical costs well; reiterating full-year trend expectationsUpdates full-year 2025 guidance to account for full-risk contract delays unrelated to core performanceALHAMBRA, Calif., Nov. 6, 2025 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (

    11/6/25 4:05:00 PM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    Astrana Health, Inc. Schedules 2025 Third Quarter Financial Results Release and Conference Call

    ALHAMBRA, Calif., Oct. 15, 2025 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced that it will release financial results for the third quarter ended September 30, 2025, after the close of the stock market on Thursday, November 6, 2025. The Company will discuss those results on a conference call at 2:30 p.m. PT/5:30 p.m. ET that same day.

    10/15/25 9:00:00 AM ET
    $ASTH
    Professional Services
    Consumer Discretionary